All News
A step change towards self-empowerment for people living with SLE
In my focus group consisting of people living with SLE and their carers, one of the keys issues raised by them was pertaining to poor reliable information about their condition. At the 2023 EULAR Congress in Milan, I learned about the wide scale dissemination and international launch of Lupus100.org project.
Read Article
New treatment for Takayasu’s arteritis?
Several studies were reported at EULAR2023 about Takayasu’s arteritis (vasculitis), a very rare large vessel vasculitis that occurs in young individuals.
Read Article
Zoster protection for JAK inhibitor patients appears achievable
One of the primary questions about JAK inhibitor safety, ever since its first approval, has been the risk of herpes zoster.
Read Article
ANCA-associated vasculitis: beyond therapy with rituximab?
Following the success of Phase 3 randomised controlled trials of non-renal and renal vasculitis, therapy with rituximab has tremendously improved the outcomes of AAV patients. However, some patients are unable to taper their glucocorticoids during rituximab therapy while others appear to be refractory to therapy, particularly those with EGPA. Hence, what are other current or future approaches beyond rituximab?
Read Article
Methotrexate - an old trusted friend who deserves better
Methotrexate (MTX) has been used as the anchor drug for the treatment of RA and PsA for many years. Despite our long experience with the use of MTX, one area that has remained uncertain is its effect on male fertility. There is now increasing evidence that cessation of MTX in males prior to trying conceive is not necessary.
Read Article
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
